Condition: Shock, Cardiogenic · Sponsor: 4TEEN4 Pharmaceuticals GmbH
The objective of this Phase 1b/2a trial is to evaluate the safety, tolerability, and exploratory efficacy of invobenitug (also known as procizumab), a monoclonal antibody under development for the treatment of cardiogenic shock (CS). CS is a life-threatening hypoperfusion of vital organs that frequently results in death. In addition to safety and tolerability, pharmacokinetics and pharmacodynamics of invobenitug are evaluated to define the optimum phase 2 dose (P2D) of invobenitug.
This description comes directly from the study's public registry record.
Karakas Mahir, Prof. Dr. Dr. · +49 173 3060687 · karakas@4teen4.de
Peter Szecsödy, MD · +46 707878737 · szecsoedy@4teen4.de
Always discuss trial participation with your own doctor first.
| Yerevan medical scientific center | Yerevan, Armenia | Not Yet Recruiting |
| Erebouni Mwdical Center | Yerevan, Armenia | Not Yet Recruiting |
| Heart Center Aalst, AZORG | Aalst, Belgium | Recruiting |
| University Hospital Saint Pierre | Brussels, Belgium | Recruiting |
| Ghent University Hospital | Ghent, Belgium | Not Yet Recruiting |
| University Hospital and Medical Faculty of Pilsen | Pilsen, Czechia | Recruiting |
| Charles University Motol University Hospital | Prague, Czechia | Recruiting |
| General University Hospital in Prague - FVN | Prague, Czechia | Recruiting |
| Institute of Clinical and Experimental Medicine - IKEM | Prague, Czechia | Recruiting |
| University Hospital Avicenne AP-HP | Bobigny, France | Recruiting |
| Département d'anesthésie-réanimation | Dijon, France | Not Yet Recruiting |
| University Hospital Lille - Institut Cœur Poumon | Lille, France | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06832722